BIOMAT Database Logo BIOMAT Database Logo

Prophylaxis of deep venous thrombosis with a low-molecular-weight heparin (Kabi 2165/Fragmin) in stroke patients. 1989

M H Prins, and R Gelsema, and A K Sing, and L R van Heerde, and G J den Ottolander
Department of Medicine, Bergweg Municipal Hospital, Rotterdam, The Netherlands.

In a group of 60 patients in the acute phase of an ischemic stroke the assumption that low-molecular-weight heparin Kabi 2165 in the dose of 2 X 2,500 anti-Xa units s.c. could prevent thromboembolic complications was tested using a double-blind, placebo-controlled, randomized trial design. Thirty patients were allocated to each group. Both treatment groups were comparable with regard to neurological status and general condition. In the Kabi 2165 group there were 6 cases of deep venous thrombosis (DVT) compared to 15 in the placebo group (p = 0.05). In the placebo group there were 4 deaths during the trial versus 9 in the Kabi-2165-treated group (NS). Cerebral bleeding complicated 2 cases in the placebo group versus 4 in the Kabi 2165 group (NS). These results indicate that in ischemic stroke patients Kabi 2165 2 X 2,500 anti-Xa units s.c./24 h reduces the frequency of DVT. Because of the small number of patients it is impossible to evaluate the safety.

UI MeSH Term Description Entries
D008297 Male Males
D002561 Cerebrovascular Disorders A spectrum of pathological conditions of impaired blood flow in the brain. They can involve vessels (ARTERIES or VEINS) in the CEREBRUM, the CEREBELLUM, and the BRAIN STEM. Major categories include INTRACRANIAL ARTERIOVENOUS MALFORMATIONS; BRAIN ISCHEMIA; CEREBRAL HEMORRHAGE; and others. Brain Vascular Disorders,Intracranial Vascular Disorders,Vascular Diseases, Intracranial,Cerebrovascular Diseases,Cerebrovascular Insufficiency,Cerebrovascular Occlusion,Brain Vascular Disorder,Cerebrovascular Disease,Cerebrovascular Disorder,Cerebrovascular Insufficiencies,Cerebrovascular Occlusions,Disease, Cerebrovascular,Diseases, Cerebrovascular,Insufficiencies, Cerebrovascular,Insufficiency, Cerebrovascular,Intracranial Vascular Disease,Intracranial Vascular Diseases,Intracranial Vascular Disorder,Occlusion, Cerebrovascular,Occlusions, Cerebrovascular,Vascular Disease, Intracranial,Vascular Disorder, Brain,Vascular Disorder, Intracranial,Vascular Disorders, Brain,Vascular Disorders, Intracranial
D005260 Female Females
D006495 Heparin, Low-Molecular-Weight Heparin fractions with a molecular weight usually between 4000 and 6000 kD. These low-molecular-weight fractions are effective antithrombotic agents. Their administration reduces the risk of hemorrhage, they have a longer half-life, and their platelet interactions are reduced in comparison to unfractionated heparin. They also provide an effective prophylaxis against postoperative major pulmonary embolism. LMWH,Low-Molecular-Weight Heparin,Low Molecular Weight Heparin,Heparin, Low Molecular Weight
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000369 Aged, 80 and over Persons 80 years of age and older. Oldest Old
D013924 Thrombophlebitis Inflammation of a vein associated with a blood clot (THROMBUS). Phlegmasia Alba Dolens,Dolens, Phlegmasia Alba,Thrombophlebitides

Related Publications

M H Prins, and R Gelsema, and A K Sing, and L R van Heerde, and G J den Ottolander
A low molecular weight heparin (KABI 2165) for prophylaxis of postoperative deep venous thrombosis.
October 1986, Acta chirurgica Scandinavica,
M H Prins, and R Gelsema, and A K Sing, and L R van Heerde, and G J den Ottolander
A comparison between low molecular weight heparin (KABI 2165) and standard heparin in the intravenous treatment of deep venous thrombosis.
December 1985, Thrombosis and haemostasis,
M H Prins, and R Gelsema, and A K Sing, and L R van Heerde, and G J den Ottolander
Low dose heparin versus low molecular weight heparin (Kabi 2165, Fragmin) in the prophylaxis of thromboembolic complications of abdominal oncological surgery.
December 1988, European journal of clinical investigation,
M H Prins, and R Gelsema, and A K Sing, and L R van Heerde, and G J den Ottolander
[Treatment of deep venous thrombosis with low molecular weight heparin (Fragmin)].
November 1991, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
M H Prins, and R Gelsema, and A K Sing, and L R van Heerde, and G J den Ottolander
Upper extremity deep venous thrombosis in cancer patients with venous access devices--prophylaxis with a low molecular weight heparin (Fragmin).
February 1996, Thrombosis and haemostasis,
M H Prins, and R Gelsema, and A K Sing, and L R van Heerde, and G J den Ottolander
Low molecular weight heparin (KABI 2165, Fragmin): pharmacokinetics after intravenous and subcutaneous administration in human volunteers.
June 1986, Thrombosis research,
M H Prins, and R Gelsema, and A K Sing, and L R van Heerde, and G J den Ottolander
[Neutralization of low molecular weight heparin Kabi 2165 by protamine chloride].
November 1986, Klinische Wochenschrift,
M H Prins, and R Gelsema, and A K Sing, and L R van Heerde, and G J den Ottolander
Effects of standard heparin and a low molecular weight heparin (Kabi 2165) on fibrinolysis.
October 1988, Thrombosis and haemostasis,
M H Prins, and R Gelsema, and A K Sing, and L R van Heerde, and G J den Ottolander
Thrombosis prophylaxis in visceral surgery with the low molecular weight heparin fragment Kabi 2165 (7,500 and 2,500 anti-Xa IU/day).
January 1986, Haemostasis,
M H Prins, and R Gelsema, and A K Sing, and L R van Heerde, and G J den Ottolander
Randomized trial of a low-molecular-weight heparin (Kabi 2165) versus adjusted-dose subcutaneous standard heparin in the prophylaxis of deep-vein thrombosis after elective hip surgery.
January 1989, Haemostasis,
Copied contents to your clipboard!